Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma

A screen for compounds that may inhibit the growth of hematological malignanciesreveals the specific dependence of some mantle cell lymphoma(MCL) cell lines on canonical or alternativeNF-κB signaling. As also seen in patients, genetic alterations affecting alternativeNF-κB signaling confer insensibility to ibrutinib, a compound that was recently approved for MCL treatment. This alternativesignaling pathway underscoresthe need to tailor treatments to the specific driving pathways in each patient group.